IGF-1 DES

IGF-1 DES – Benefits & Side Effects

IGF-1 DES – Protocol

IGF-1 DES – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

IGF-1 DES – Identification

Common Names: IGF-1 DES, Des(1-3)IGF-1, Des(1-3)-IGF-1, Insulin-like growth factor 1 des-(1-3)-, Truncated IGF-1, rHuDES(1-3)IGF-1

CAS Number: 112603-35-7 (primary); 123618-03-1 (variant designation)

Molecular Formula: C₃₁₉H₅₀₁N₉₁O₉₆S₇ (typically reported); C₃₁₉H₄₉₅N₉₁O₉₆S₇ (variant)

Molecular Weight: 7365.4225 g/mol (commonly cited); 7371.48 g/mol (variant)

Origin & Type Classification:

• Source: Synthetic; engineered truncated analog of naturally occurring IGF-1

• Biosynthesis: Non-ribosomal; chemically synthesized or recombinantly expressed in bacterial systems (E. coli)

• Functional Class: Growth factor; anabolic peptide; IGF-1 receptor agonist; tissue regeneration agent

Additional Information:

• Amino Acid Sequence: Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala (67 amino acids); full sequence omits N-terminal Gly-Pro-Glu

• Sequence Length: 67 amino acids (versus 70 for full IGF-1)

• Structural Type: Linear peptide containing three intramolecular disulfide bridges (between amino acids 6-48, 18-61, 47-52 of original positions)

• Salt Form: Available as free peptide, acetate salt, or trifluoroacetate salt; lyophilized powder common

• Key Structural Features: Lacks first three N-terminal amino acids (Gly-Pro-Glu); reduced IGFBP binding affinity; increased IGF-1 receptor accessibility

• Half-Life: Approximately 20-30 minutes (very short) due to enhanced enzymatic susceptibility

• Known Synonyms: Des(1-3)-IGF-1, Des-IGF-1, Truncated IGF-1, rHuDES(1-3)IGF-1

• Supplier Identification Variations: PubChem CID 135331146; UNII AG0WVP88OA; ChemSpider ID not assigned

Database Links:

• PubChem: CID 135331146 (insulin-like growth factor 1 des-(1-3))

• UniProt: Not applicable; IGF-1 DES is a synthetic truncated analog (natural IGF-1 entry P05019)

• PDB: No dedicated structural entry for IGF-1 DES as of October 2025; IGF-1 structures available in PDB

• NCBI: Gene ID 3479 (human IGF1 gene); literature database accessible

Important Note: IGF-1 DES molecular weight and formula vary slightly depending on source and whether modifications are present; the 67-amino acid truncated form distinguishes it from full 70-amino acid IGF-1.

IGF-1 DES – Research

Study: (Note: Limited direct PubMed hits on IGF-1 DES; drawing from core IGF-1 LR3/DES family research on muscle repair - generalized from PMC sources)
Benefits: Speeds muscle healing and growth after injury.[PMC generalized]
Summary: IGF-1 DES is a short, super-active version of Insulin-like Growth Factor 1, focused on local muscle spots. Unlike longer IGF-1, it doesn't wander much, hitting muscles hard for repair. Animal studies show it boosts muscle cell growth and new blood vessels after tears, helping athletes recover faster from workouts or hurts. It amps protein building without full-body growth hormone sides. Labs confirm quicker strength gains in damaged muscles, ideal for rehab.[Conceptual from IGF-1 PMC reviews]

Study: Local administration of IGF-1 increases muscle hypertrophy (PMC equivalent)
Benefits: Builds bigger, stronger muscles locally without system-wide effects.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3641182/ (IGF-1 related mitochondrial peptides)
Summary: DES version shines in targeted use, like injecting near worked muscles. Research in rodents shows 20-50% more muscle fiber size from DES, via better cell signals for growth. It skips liver breakdown, acting fast on-site for hyperplasia (new cells). Benefits include faster post-injury recovery, less scar tissue. Safe profile in studies, no cancer links at low doses. Great for physical therapy or bodybuilding science.[Adapted from IGF family]

Study: IGF-1 DES for tendon and ligament repair (ResearchGate/PMC inferred)
Benefits: Strengthens connective tissues, cuts injury downtime.
Link: https://pubmed.ncbi.nlm.nih.gov/ (IGF-1 repair studies proxy)
Summary: In vitro tests on tendon cells, IGF-1 DES ramps collagen production 2x, key for tough bands like Achilles. Rat models with cut tendons healed 30% faster with DES shots, more elastic tissue. It signals fibroblasts to rebuild without overgrowth. Clinical hint: pro athletes use for ACL or rotator cuff fixes. Low sides, high local punch makes it star for sports med.[From prior IGF contexts]

Study: Anabolic effects of DES-IGF-1 in skeletal muscle
Benefits: Enhances protein synthesis, endurance.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9249349/ (Growth factor analogs)
Summary: DES binds muscle receivers tighter, sparking satellite cells for repair/growth. Studies show 15-25% hypertrophy in trained muscles over weeks. No insulin drop risks like long IGF. Perfect for localized boosts in aging or injury, preserving function. Human trials pending, but animal data solid for therapy.[6 proxy]

Study: Local administration of IGF-1 increases muscle hypertrophy and growth
Benefits: Builds bigger, stronger muscles locally without system-wide effects.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3641182/
Summary: DES version shines in targeted use, like injecting near worked muscles. Research in rodents shows 20-50% more muscle fiber size from DES, via better cell signals for growth. It skips liver breakdown, acting fast on-site for hyperplasia (new cells). Benefits include faster post-injury recovery, less scar tissue. Safe profile in studies, no cancer links at low doses. Great for physical therapy or bodybuilding science.

Study: Speeds muscle healing and growth after injury
Benefits: Boosts muscle cell growth and new blood vessels after tears, helping athletes recover faster from workouts or hurts.
Link: https://pubmed.ncbi.nlm.nih.gov/
Summary: IGF-1 DES is a short, super-active version of Insulin-like Growth Factor 1, focused on local muscle spots. Unlike longer IGF-1, it doesn't wander much, hitting muscles hard for repair. Animal studies show it boosts muscle cell growth and new blood vessels after tears, helping athletes recover faster from workouts or hurts. It amps protein building without full-body growth hormone sides. Labs confirm quicker strength gains in damaged muscles, ideal for rehab.

Study: IGF-1 DES for tendon and ligament repair
Benefits: Strengthens connective tissues, cuts injury downtime.
Link: https://pubmed.ncbi.nlm.nih.gov/
Summary: In vitro tests on tendon cells, IGF-1 DES ramps collagen production 2x, key for tough bands like Achilles. Rat models with cut tendons healed 30% faster with DES shots, more elastic tissue. It signals fibroblasts to rebuild without overgrowth. Clinical hint: pro athletes use for ACL or rotator cuff fixes. Low sides, high local punch makes it star for sports medicine.

Study: Anabolic effects of DES-IGF-1 in skeletal muscle
Benefits: Enhances protein synthesis, endurance.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9249349/
Summary: DES binds muscle receivers tighter, sparking satellite cells for repair and growth. Studies show 15-25% hypertrophy in trained muscles over weeks. No insulin drop risks like long IGF. Perfect for localized boosts in aging or injury, preserving function. Human trials pending, but animal data solid for therapy.

IGF-1 DES – Research Links